The data are not publicly available due to restrictions e.g. their containing information that could compromise the privacy of research participants. Although the identity of the research objects are protected by a code key, the GPS coordinates could be used to identify individual participtants. Data can be made available from Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden - if the request is approved by the Ethics Committee. Contact via <rccnorr@umu.se>.

Introduction {#sec005}
============

Long travel distance and long travel time to care have been linked to poor outcomes in patients with malignant diseases \[[@pone.0236799.ref001]--[@pone.0236799.ref003]\]. These findings might reflect barriers to access of care, possibly increasing risk not only for delayed diagnosis and suboptimal treatment, but also for lower patient participation in screening programs and follow-up care.

Several studies have found evidence of poor survival in patients with colorectal cancer who reside in rural areas \[[@pone.0236799.ref003]--[@pone.0236799.ref005]\]. In many of these studies, a more advanced stage at diagnosis was found in patients who travelled long distances to receive care, findings that suggest stage at diagnosis is a mediator to an unfavourable outcome \[[@pone.0236799.ref004], [@pone.0236799.ref005]\]. In addition, advanced disease stage at diagnosis increases the risk for emergency surgery, which is an independent risk factor for poor survival in colorectal cancer \[[@pone.0236799.ref006], [@pone.0236799.ref007]\]. There is also evidence that provisions for surgical and oncological treatments differ between rural and urban areas \[[@pone.0236799.ref004], [@pone.0236799.ref008]\]. However, differences in colorectal cancer survival attributed to distance to care might in part be explained by sociodemographic differences between rural and urban populations.

In many areas in Europe and the U.S., the rural population is older and has a lower socioeconomic status compared with urban populations \[[@pone.0236799.ref009], [@pone.0236799.ref010]\]. Both older age and low socioeconomic status have been associated with poorer prognosis in colorectal cancer \[[@pone.0236799.ref011], [@pone.0236799.ref012]\]. In addition, there may be differences between rural and urban areas in the proportion of persons living alone, a factor that has been shown to adversely affect outcomes in colorectal cancer \[[@pone.0236799.ref011]--[@pone.0236799.ref013]\].

Recently, we published a study that found lower survival for patients with colon cancer in the Northern Healthcare Region in Sweden, compared with the rest of the country \[[@pone.0236799.ref012]\]. The Northern Healthcare Region has approximately 900 000 inhabitants living in an area of 224 000 km^2^, resulting in a population density of only 4 pop./km^2^. (U.K. ≈ 260 pop./km^2^, France ≈ 100 pop./km^2^) \[[@pone.0236799.ref014], [@pone.0236799.ref015]\]. The Region includes many rural areas where patients have to travel long distances to reach the nearest hospital ([Fig 1](#pone.0236799.g001){ref-type="fig"}). In our earlier study, we proposed that on average longer distance to health care might contribute to the poor survival observed in the Northern Region. This study investigates whether travel time to the nearest hospital in the Northern Healthcare Region is associated with survival in patients diagnosed with colorectal cancer.

![Map of the Northern Health Care Region of Sweden with hospitals.\
Hospitals: A Kiruna, B Gällivare, C Kalix, D Sunderbyn, E Piteå, F Skellefteå, G Lycksele, H Umeå (University Hospital), I Örnsköldsvik, J Sollefteå, L Härnösand, M Sundsvall, K Östersund. (Source: The Swedish Mapping Authority (Lantmäteriet), available according to open data license Creative Commons, CC0).](pone.0236799.g001){#pone.0236799.g001}

Methods {#sec006}
=======

This cohort study is based on information retrieved from the Risk North database, which includes all men and women diagnosed with colorectal cancer in the Northern Healthcare Region between January 1st 2007 and December 31st 2013. The Risk North database was constructed to study associations between sociodemographic factors, cancer management, and cancer survival in the Northern Healthcare Region of Sweden. To enable studies on cancer disparities between the Northern Health Care Region and the rest of the country, the database also includes data on patients residing in other Swedish regions. The Risk North project and database has been described in detail earlier \[[@pone.0236799.ref012]\].

Briefly, the database was generated by means of individual level record linkages between three national cancer quality registries (the Colorectal Cancer Registry, the Oesophageal and Gastric Cancer Registry, and the Brain Tumour Registry) and other demographic and health care registries ([S1 Fig](#pone.0236799.s001){ref-type="supplementary-material"}). Combining data from the same individual from different data sources is possible because the Swedish government issues a personal identity number to all individuals in Sweden at birth or time of permanent residency. This identity number is used to track the use of all health care services.

Original sources of data in Risk North used in the present study {#sec007}
----------------------------------------------------------------

The data in the Risk North database used in the present study originates from five different registries: Swedish Colorectal Cancer Registry (SCRCR), Cause of Death Register (CDR), Geography Database (GD), Total Population Register (TPR), and Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA).

### Swedish Colorectal Cancer Registry (SCRCR) {#sec008}

The SCRCR is a national quality registry with the primary purpose to monitor management and outcomes. To ensure that no patients are missed, the SCRCR is cross-matched with the National Cancer Registry, resulting in 98% level of completeness \[[@pone.0236799.ref016]\].

Since the start of the registry in 1995, data from the SCRCR have been used in many scientific studies \[[@pone.0236799.ref017], [@pone.0236799.ref018]\].

The present study uses the following variables from the SCRCR: hospital, age, gender, tumour stage, elective surgery, and emergency surgery. In the SCRCR, tumour stage is recorded according to the Union for International Cancer Control (UICC) TNM classification 7^th^ edition. Stage is primarily based on histopathological staging of surgical specimens (pTNM), if histopathology is missing---clinical staging (imaging) is used (cTNM). Emergency surgery is defined as an operation during an unplanned admission as the result of an acute medical condition such as bowel obstruction or perforation.

### The Cause of Death Registry (CDR) {#sec009}

The CDR, part of the National Board of Health and Welfare, includes date of and causes of death for every diseased individual in Sweden. The level of completeness is very high and in patients with malignant disease the validity of the recorded cause of death has been estimated to be around 90% \[[@pone.0236799.ref019]\]. In this study, we used the CDR to obtain information on date and cause of death. Cause-specific death was defined as a death where colon or rectal cancer was listed as the main cause or one of first two contributing causes.

### Geography Database (GD) {#sec010}

The GD links personal identity number to GPS coordinates of the patient's registered address. The coordinates of the patient's address the year before the diagnosis was used to calculate travel time to hospital. The precision of the coordinates is 250 x 250 m in urban areas and 1000 x 1000 m in rural areas.

### The Total Population Registry (TPR) {#sec011}

The TPR contains information on age, sex, and registered addresses for the entire Swedish population. We used the TPR to determine whether a patient was living alone or co-habiting the year before diagnosis.

### Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA) {#sec012}

LISA merges several registries covering health insurance and the Swedish labour market and contains individual information on socioeconomic factors such as income and educational level. Previous studies have suggested that education represents the best predictor for socioeconomic-related health outcomes \[[@pone.0236799.ref020]\]. Consequently, we used the highest level of education as a measure of socioeconomic status. Level of education was defined as low (up to nine years of compulsory school), middle (2 to 3 years of secondary education), or high (university).

Statistical analysis {#sec013}
--------------------

In the analyses of possible associations between travel time and colorectal cancer survival, several potential confounders or mediators were considered: age, socioeconomic status, co-habiting status, tumour stage, proportion of emergency operations, and proportion of surgical resection. To test for proposed associations, we used two-sided between-subject Student's t-test for continuous parametric variables and Spearman's test for non-parametric ranked variables (α = 0.05).

### Assessments of travel time {#sec014}

We measured travel time by car from the patient's home address to the nearest hospital with facilities to diagnose and stage colorectal cancer (i.e., endoscopy and/or radiology department). For operated patients, we also measured travel time to the operating hospital registered in the SCRCR. For the location of the hospitals, see [Fig 1](#pone.0236799.g001){ref-type="fig"}. Coordinates for the hospitals were retrieved from a Swedish search engine, Eniro.se \[[@pone.0236799.ref021]\].

All travel time calculations were performed with ArcGIS^®^ Pro (2.1.2) and ArcGIS online (Esri, Redlands, CA, USA). For each hospital in the Northern Region, we created 10-minute interval drive time areas: 0--10; \>10--20; \>20--30; ...; \>290--300. We used default settings of the 'Rural driving time mode' in ArcGIS^®^, as traffic rarely hampers transportation in Northern Sweden. Individual driving times for each patient were then identified using the ArcGIS^®^ tool 'Spatial Join'.

### Survival analysis {#sec015}

Colorectal cancer-specific survival was defined as the time from date of diagnosis to date of death attributed to colorectal cancer. Patients were censored at time of death due to other causes, emigration abroad, or at the end of follow-up (31 December 2014).

In our main survival analysis, travel time was handled as a continuous variable, using the lowest value in the above-described 10-minute intervals.

In univariable analysis, Kaplan-Meier estimates were used to plot survival in patients with different travel times, and Cox regression analysis was used to estimate hazard ratios (HRs) of death with 95% CI for patients with different travel times.

For multivariable analysis, multiple Cox regression analysis was used to estimate hazard ratios (HRs) of death with 95% CI for patients with different travel times. This analysis was stratified by age (10-year groups) and gender and adjusted for stage, educational level, co-habiting status, and emergency surgery.

Patients were excluded if data were missing for any of the co-variables in the multivariable analysis, and consequently we excluded all non-operated patients (missing data on the variable operation).

In all Cox models, the proportional hazard assumption was tested.

We performed a sensitivity analysis of the results in the main multiple Cox regression by varying end-points, input variables, and adjusted factors.

We also performed an additional multiple Cox regression survival analysis, where we handled travel time as a categorical variable---comparing survival in patients traveling \< 1 h vs. patients traveling \>1 h.

We used R version 3.6.0 for the statistical analysis (R Core Team) \[[@pone.0236799.ref022]\].

Ethics {#sec016}
======

The Regional Board of Ethics in Umeå approved the design of the Risk North database and the present research project---approval number: 2014/278-31. All colorectal cancer patients in Sweden are informed about registration in the SCRCR (i.e. the primary source of data in the present study) and an opt-out procedure for registration is used in the SCRCR. The data in the Risk North Database is not publicly available according to the Swedish data protection law. The patients did not provide informed written consent but all data were fully anonymised before access.

Results {#sec017}
=======

During the study period (2007--2013), 3721 men and women were diagnosed with colorectal cancer in the Northern Healthcare Region and registered in the SCRCR. Three patients were excluded because of missing geographical coordinates, thus the final study population included 3718 patients ([Table 1](#pone.0236799.t001){ref-type="table"}). The mean travel time to nearest hospital was 23.85 minutes with standard deviation 33.67. About one-third (36.8%) of the patients had less than 10 minutes travel time to a hospital that provides care ([Fig 2](#pone.0236799.g002){ref-type="fig"}). The five-year cause-specific survival rate for all included colorectal patients was 64% (colon: 64%; rectal: 63%).

![Distribution of travel time (minutes) to nearest hospital for patients with colorectal cancer residing in the Northern Region of Sweden.](pone.0236799.g002){#pone.0236799.g002}

10.1371/journal.pone.0236799.t001

###### Distribution of sociodemographic and tumour characteristics in 3718 patients residing in the Northern Region and diagnosed with colorectal cancer between 2007 and 2013.

![](pone.0236799.t001){#pone.0236799.t001g}

                                                      N (%)        Missing (%)   Total
  --------------------------------------------------- ------------ ------------- -------
  **Gender**                                                                     
   Male                                               1970(53.0)   11(0.3)       3718
   Female                                             1737(47.0)                 
  **Tumour location**                                                            
   Colon                                              2463(66.2)   2(0.05)       3718
   Rectum                                             1253(33.8)                 
  **Tumour stage**                                                               
   I                                                  563(15.1)                  3718
   II                                                 1005(27.0)   300(8.1)      
   III                                                1063(28.6)                 
   IV                                                 787(21.2)                  
  **Surgery**[^1^](#t001fn001){ref-type="table-fn"}                              
   Yes                                                3248(87.4)   0             3718
   No or missing data                                 470(14.5)                  
  **Educational level**                                                          
   Low                                                1545(41.6)   18(0.005)     3718
   Middle                                             1509(40.6)                 
   High                                               646(17.4)                  
  **Co-Habiting status**                                                         
   Living Alone                                       1577(42.4)   0             3718
   Co-habiting                                        2141(57.6)                 

^1^Operation; Yes includes any operation recorded---curative or palliative, whereas No represents no surgery recorded or performed.

Missing data was \< 1% for variables gender, tumour location, educational level and co-habiting status ([Table 1](#pone.0236799.t001){ref-type="table"}). For tumour stage, 300 patients (8.1%) had missing data. Three patients were lost to follow-up in the survival analysis.

No of patients in each time interval: $$\begin{matrix}
{0 - 10\mspace{720mu} 1371\left( {37\%} \right)} & {> 10 - 20\mspace{720mu} 827\left( {22\%} \right)} & {> 20 - 30\mspace{720mu} 338\left( {9\%} \right)} & {> 30 - 40\mspace{720mu} 284\left( {8\%} \right)} \\
\end{matrix}$$ $$\begin{matrix}
{> 40 - 50\mspace{720mu} 199\left( {5\%} \right)} & {> 50 - 60\mspace{720mu} 183\left( {5\%} \right)} & {> 60 - 70\mspace{720mu} 92\left( {2\%} \right)} & {> 70 - 80\mspace{720mu} 129\left( {3\%} \right)} \\
\end{matrix}$$ $$\begin{matrix}
{> 80 - 90\mspace{720mu} 44\left( {1\%} \right)} & {> 90 - 100\mspace{720mu} 29\left( {1\%} \right)} & {> 100 - 110\mspace{720mu} 22\left( {1\%} \right)} & {> 110\mspace{720mu} 110\left( {3\%} \right)} \\
\end{matrix}$$

Patient characteristics and travel time {#sec018}
---------------------------------------

We found associations between longer travel time and older age (p = 0.044), lower educational level (socioeconomic status) (p \< 0.001), and living alone (p = 0.003) ([Table 2](#pone.0236799.t002){ref-type="table"}; [S2](#pone.0236799.s002){ref-type="supplementary-material"}--[S4](#pone.0236799.s004){ref-type="supplementary-material"} Figs). No significant differences in tumour stage at diagnosis were found with respect to travel time to the nearest hospital ([Table 2](#pone.0236799.t002){ref-type="table"}; [S5 Fig](#pone.0236799.s005){ref-type="supplementary-material"}) (p = 0.96). The risk for emergency surgery was not associated with travel time, or the proportion of non-operated patients (p = 0.767) ([Table 2](#pone.0236799.t002){ref-type="table"} and [S6 Fig](#pone.0236799.s006){ref-type="supplementary-material"}).

10.1371/journal.pone.0236799.t002

###### The patient´s characteristic---Mean age, level of education, co-habiting status, tumour stage at diagnosis and type of surgery---Stratified by travel time to the nearest hospital.

![](pone.0236799.t002){#pone.0236799.t002g}

                                                                       Travel time (min)                                                                                                       
  -------------------------------------------------------------------- ------------------- -------------- -------------- ------------- ------------- ------------- ------------ -------------- -----------------------------------------------
  **No. of patients**                                                  1371                827            338            284           199           183           92           424            
  **Mean age yrs**                                                     70.7                70.2           69.7           70.3          71.6          73.2          72.7         72.4           0.044[^1^](#t002fn001){ref-type="table-fn"}
  **Level of education N (%)**[^2^](#t002fn002){ref-type="table-fn"}                                                                                                                           
  Low                                                                  499(36)             304(37)        142(42)        139(49)       108(54)       90(49)        48(52)       215(51)        \<0.001[^3^](#t002fn003){ref-type="table-fn"}
  Middle                                                               555(40)             377(46)        141(42)        105(37)       69(35)        69(38)        35(38)       158(37)        
  High                                                                 312(23)             144(17)        51(15)         39(14)        20(10)        24(13)        8(9)         48(11)         
  Missing                                                              18                                                                                                                      
  **Co-habiting (%)**[^2^](#t002fn002){ref-type="table-fn"}                                                                                                                                    
  Proportion of patients living alone                                  609/1371 (44)       315/827 (38)   119/338 (35)   83/284 (40)   81/199 (42)   38/183 (44)   60/92 (41)   272/424 (51)   0.003[^3^](#t002fn003){ref-type="table-fn"}
  **Tumour stage (%)**[^2^](#t002fn002){ref-type="table-fn"}                                                                                                                                   
  I                                                                    226(16)             111(13)        50(15)         37(13)        30(15)        29(16)        17(18)       63(15)         0.431[^3^](#t002fn003){ref-type="table-fn"}
  II                                                                   373(27)             221(27)        85(25)         90(32)        51(26)        50(27)        25(27)       110(26)        
  III                                                                  383(28)             244(30)        101(30)        68(24)        62(31)        47(26)        26(28)       132(31)        
  IV                                                                   282(21)             181(22)        73(22)         66(23)        41(21)        48(26)        14(15)       82(19)         
  Missing                                                              107(8)              70(8)          29(9)          23(8)         15(8)         9(5)          10(11)       37(9)          
  **Type of surgery (%)**[^2^](#t002fn002){ref-type="table-fn"}                                                                                                                                
  Elective                                                             962(70)             575(70)        241(71)        195(69)       131(66)       127(69)       65(71)       309(73)        0.767[^3^](#t002fn003){ref-type="table-fn"}
  Emergency                                                            180(13)             115(14)        39(12)         43(15)        33(17)        23(13)        10(11)       50(12)         
  Not operated or missing                                              229(17)             137(17)        58(17)         46(16)        35(18)        33(18)        17(18)       65(15)         

^1^ Student's t-test.

^2^ Percentages may not total 100 due to rounding.

^3^ Spearman's test.

Analysis of the impact of travel time on colorectal cancer survival {#sec019}
-------------------------------------------------------------------

In the univariable analysis including all patients, there were no significant differences in cause-specific survival in relation to travel time to the nearest hospital for colon (HR 1.001; 95% CI 0.9985--1.003) or rectal cancer (HR 0.9983; 95% CI 0.9952--1.002).

[Fig 3](#pone.0236799.g003){ref-type="fig"} graphically represents univariable survival by different travel times in a Kaplan-Meier plot.

![Kaplan-Meier plots for cause-specific survival for patients with colon and rectal cancer respectively by travel time to the nearest hospital.](pone.0236799.g003){#pone.0236799.g003}

The main multiple Cox regression analysis (restricted to operated patients) revealed no statistically significant differences in cause-specific survival in relation to travel time. However, survival was significantly lower in colon cancer patients living alone and in patients who had emergency surgery or advanced stage cancer at diagnosis ([Table 3](#pone.0236799.t003){ref-type="table"}).

10.1371/journal.pone.0236799.t003

###### Hazard ratios of cause-specific survival for operated patients estimated in a multiple cox regression analysis; stratified by sex and age at diagnosis (10-year groups) and adjusted for educational level, cohabiting status, elective/emergency surgery and tumour stage.

![](pone.0236799.t003){#pone.0236799.t003g}

                            Colon Cancer   Rectal Cancer           
  ------------------------- -------------- --------------- ------- --------------
  **Travel time**           0.999          0.997--1.002    0.997   0.992--1.002
  **Education level**                                              
   Low (ref)                1 (ref)                        1       
   Medium                   0.96           0.78--1.17      0.86    0.60--1.002
   Higher                   0.87           0.67--1.14      1.05    0.66--1.66
  **Cohabitation status**                                          
   Living alone (ref)       1(ref)                         1       
   Not living alone         0.77           0.64--0.93      0.77    0.56--1.07
  **Operation**                                                    
   Elective (ref)           1 (ref)                        1       
   Emergency                2.66           2.21--3.20      5.5     2.69--11.3
  **Tumour stage**                                                 
   I (ref)                  1 (ref)                        1       
   II                       1.66           0.94--2.91      2.76    1.44--5.26
   III                      6.15           3.63--10.4      3.98    2.13--7.42
   IV                       22.9           13.5--38.9      20.7    10.8--39.7

The stability of the results in the main multivariable regression survival analysis was assessed with a sensitivity analysis. In these analyses, the association between travel time and survival was examined in five other settings: 1) colorectal cancer survival handled as one entity rather than colon and rectal cancer separately; 2) over-all cancer survival rather than cause-specific survival; 3) cause-specific survival without adjusting for tumour stage and emergency operations; 4) travel time to the operating hospital rather than the nearest hospital; and 5) the exclusion of all patients with tumour stage IV.

In all five of these alternative models, the results remained robust: there was no association between travel time and survival ([S1](#pone.0236799.s007){ref-type="supplementary-material"}--[S5](#pone.0236799.s011){ref-type="supplementary-material"} Tables).

In the additional multivariable regression survival analysis where travel time was handled as a categorical variable (survival for patients with travel time \< 1 h was compared to patients traveling \> 1 h) we found no association between travel time and survival, either for patients with colon cancer HR 0.92\[95% CI 0.71--1.19\] or rectal cancer HR 0.84 \[95% CI 0.52--1.36\] ([S6 Table](#pone.0236799.s012){ref-type="supplementary-material"}).

Discussion {#sec020}
==========

Longer travel time to the nearest hospital for patients with colorectal cancer was associated with older age, lower socioeconomic status, and living alone. However, we found no evidence of an association between travel time and stage at diagnosis or colorectal cancer survival.

Our study´s lack of an association between travel time to care and CRC survival is in contrast to the results of most other studies \[[@pone.0236799.ref002]--[@pone.0236799.ref005], [@pone.0236799.ref008], [@pone.0236799.ref023]--[@pone.0236799.ref025]\]. However, it is unclear to what extent previously observed associations between longer distance to care and poor colorectal cancer survival reflects access to care or confounding factors such as age, socioeconomic factors, and co-morbidity. One proposed mechanism for a direct distance--survival effect is late diagnosis due to less access to care, resulting in a more advanced tumour stage at diagnosis. In contrast to most other studies, we found no association between travel time and tumour stage at diagnosis \[[@pone.0236799.ref004], [@pone.0236799.ref005], [@pone.0236799.ref008], [@pone.0236799.ref026]\]. This finding might explain our study's overall absence of associations between travel time and survival.

Corroborating results from earlier studies, we observed differences between rural and urban patients with respect to age and socioeconomic factors. However, these differences did not appear to negatively influence the survival for the patients with longer distances to care.

There are factors in the organisation of the health care system in the Northern Health Care Region in Sweden, which may mitigate health care disparities associated with longer distance to care:

The national health care system in Sweden is tax funded and provides care to all residents at low out-of-pocket cost \[[@pone.0236799.ref027]\]. In addition, all patients in Sweden are entitled to free or subsidized travel to care. All 13 hospitals in the Northern Health Care Region are publicly owned and all have facilities to diagnose colorectal cancer. Each local hospital offers service to the population in its catchment area. The population, which is served per hospital, varies from approximately 25000 to 160000 \[[@pone.0236799.ref014]\]. Surgical treatment, especially for rectal cancer, has however been centralised to fewer hospitals in the Region during the study period. By the end of the study period, rectal cancer surgery was performed at only five hospitals.

Chemotherapy is given at most local hospitals under guidance from the only Oncology departments in the Region, located in Umeå and Sundsvall. In summary, all colorectal cancer patients in the Region can go to their local hospital, at a low cost, for diagnosis and in most cases also for treatment.

In a non-universal health care setting, socioeconomic differences between urban and rural populations could affect the access to care more than the distance to care itself. However, many of the previous studies in this research field from the U.S. adjusted for socioeconomy as a confounding factor, but still reported associations between longer travel time and worse colorectal cancer outcomes \[[@pone.0236799.ref002], [@pone.0236799.ref004], [@pone.0236799.ref008]\].

Associations between longer distance to care and worse survival have also been reported in European countries with national universal health care systems such as France or the U.K. \[[@pone.0236799.ref005], [@pone.0236799.ref023]\]. Thus, true distance-related barriers, not confounded by differences in the patient´s socioeconomy, are probably also present and important in countries with universal health care.

Subsidized travel to care could be one way to mitigate distance related barriers to care. A study from Norway, with the same population pattern and health care system as Sweden, found no association between travel distance and cancer survival \[[@pone.0236799.ref028]\]. In both Sweden and Norway, all patients are entitled to free or subsidized travel to care \[[@pone.0236799.ref029], [@pone.0236799.ref030]\]. In other universal (e.g., U.K.) or mixed health care systems (e.g., Australia), support with travel costs are based on income and/or distance to the caregiver \[[@pone.0236799.ref031], [@pone.0236799.ref032]\]. The potential role of free or subsidized travel deserves more attention, especially with regard to patient adherence to repeated oncological treatment and outcome.

From a health care system perspective, another distance-related barrier to care could be difficulties for rural GPs to refer their patients to hospitals in urban areas. The facilitation of swift referrals from GPs is one of the concepts in so-called 'rapid cancer diagnostic and assessment pathways' in the U.K. or 'standardised cancer care pathways in Sweden \[[@pone.0236799.ref033], [@pone.0236799.ref034]\]. During our study period, neither standardised cancer care pathways, nor colorectal screening had been implemented in the studied region. Travel time studies from the U.K. (Scotland) with implemented cancer pathways still show an association between travel time and poorer cancer outcomes \[[@pone.0236799.ref003]\].

Centralising care with the intention of improving the standard of care can also introduce a barrier to care---*if* travel time is associated with poorer outcomes \[[@pone.0236799.ref025]\]. As mentioned above, there has been a trend towards centralising surgery to fewer hospitals in the Northern Health Care Region, especially for rectal cancer. However, in one of the settings in our sensitivity analysis, we analysed travel time to the operating hospital rather than the nearest hospital. The results were the same: no association between travel time and survival was found.

Finally, there might be other factors---not related to the health care system---which explains the good outcome in Northern Sweden. As suggested in a Norwegian study, individuals living in rural areas might be more used to travel far in their everyday life---thus reducing travel distance as a barrier to care \[[@pone.0236799.ref028]\].

There are some methodological differences between our study and studies reporting an association between travel distance and survival. First, we measure travel time to care, whereas travel distance has been more commonly studied \[[@pone.0236799.ref005], [@pone.0236799.ref008], [@pone.0236799.ref023], [@pone.0236799.ref024]\]. Most studies, however, define place of care similarly to our study--i.e., the nearest hospital--but a few studies have also measured distance to a general practitioner (GP) \[[@pone.0236799.ref003], [@pone.0236799.ref026]\]. Furthermore, we used Geographical Information System (GIS) technology to measure individual travel time by car. In contrast, some studies use straight line or great circle approximations of distances from place of residence to hospitals.

In our main survival analysis, we handled travel time as a continuous variable with 10-minute intervals rather than categorizing travel distance into, for example, quintiles or different cut-off values \[[@pone.0236799.ref003], [@pone.0236799.ref008], [@pone.0236799.ref024]\]. This was done to avoid any presumptions on what is a meaningful travel time difference. When we handled travel time as categorical variable (\< 1 h vs. \> 1 h) in our additional setting for the survival analysis, no association between travel time and survival was found.

All these methodological differences may limit comparability, although probably not the validity, of our results.

Limitations {#sec021}
-----------

The relatively few patients with long travel time to the nearest hospital constitute a potential lack of statistical power and an important limitation in our study. Only 516/3718 ≈ 14% of the patients had \> 1 h travel time to their nearest hospital. This reflects that most of the population in Northern Sweden are concentrated in and near the cities. However, the proportion of patients with \> 1 h travel time is in line with or higher than most other studies \[[@pone.0236799.ref003], [@pone.0236799.ref005], [@pone.0236799.ref008], [@pone.0236799.ref023]\]. Another potential limitation is the validity on causes of death data. To minimize the impact of co-morbidity, we analysed cause-specific instead of all-cause mortality. The validity of the cause of death for malignant disease in the Swedish Causes of Death Registry is approximately 90%, but there might be differential bias between rural and urban areas \[[@pone.0236799.ref019]\] There may also be information bias due to missing data on stage of disease at time of diagnosis, as no information on stage was available for 300 of the studied patients (≈8%).

Strengths {#sec022}
---------

The main strength of this study is the use of the Risk North population-based approach, a strategy that enables a health care system perspective based on individual data linked to health care and sociodemographic registries. This linkage enables precise computerized measurement of travel time as well as individual-specific information on possible confounders for a proposed travel time--survival association. Thanks to Sweden's assignment of personal identity numbers, only three patients moving abroad were lost for follow-up in the survival analysis.

Conclusions {#sec023}
===========

In contrast to earlier results from studies conducted in variety of settings, we found no association between travel time to the nearest hospital and stage of disease at time of diagnosis and survival in colorectal cancer. Thus, in the geographical setting of the Northern Health Care Region in Sweden, travel time to care does not appear to negatively influence colorectal cancer outcomes. The results suggest that the Swedish health care system manages to equalize disparities associated with travel distance to care. Future studies should compare different health care systems to identify factors that facilitate access to care in rural areas.
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Hazard ratios of cause-specific survival in colorectal cancer for operated patients estimated in a multiple cox regression analysis; stratified by sex and age at diagnosis (10-year groups) and adjusted for educational level, cohabiting status, elective/emergency surgery and tumour stage.
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###### Sensitivity analysis, results for analysing cause-specific survival without adjusting for tumour stage and emergency operations.
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###### Sensitivity analysis, results for analysing travel time to the operating hospital.

Hazard ratios of cause-specific survival for operated patients estimated in a multiple cox regression analysis; stratified by sex and age at diagnosis (10-year groups) and adjusted for educational level, cohabiting status, elective/emergency surgery and tumour stage.
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###### Sensitivity analysis, results when excluding patients with tumour stage IV.

Hazard ratios of cause-specific survival for operated patients estimated in a multiple cox regression analysis; stratified by sex and age at diagnosis (10-year groups) and adjusted for educational level, cohabiting status, elective/emergency surgery and tumour stage.
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###### Additional setting of the multivariable regression survival analysis, travel time handled as a categorical variable; survival for patients with travel time \< 1 h compared to patients traveling ≥1 h.
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###### Regression analyses for travel time and survival.
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Dear Editor!

Thank you for your comments and suggestions to improve our research and manuscript, we have successfully been able to adjust the manuscript on several points and now feel that it has improved. We now hope that it is possible to accept in its current revised form.

Our responds are given point by point below and highlighted in the manuscript.

Best Wishes, Olle Sjöström, Corresponding author.

Additional Editor Comments (if provided):

Figures should stand alone. Please provide values on figures and details in the figure legends. For example, figure 2 does not have information on %.

Thank you for this comment. We have added figures and values accordingly. Please see the revised figures.

Please provide location, name and etc. in figure 1.

Please see the new Figure 1. The travel time isochrones has been removed and replaced with name and location of the hospitals.

Only multivariate analysis results, which are main findings, can be presented in the abstract.

Please see the revised abstract, we have removed all results other results:

Results

No association between travel time and survival was observed, either in univariable analysis (colon HR 1.00 \[95% CI 0.998 - 1.003\]; rectal HR 0.998; \[95% CI 0.995 -1.002\]) or in multivariable Cox regression analysis (colon HR 0.999 \[95% CI 0.997 - 1.002\]; rectal HR 0.997 \[95% CI 0.992- 1.002\]).

Please provide characteristics (age, tumor stage, SES, surgery, cohabiting status, tumor location and etc.) of participants according to travel time (e.g. whether they were older with longer travel time?) instead of figures (cannot see well in the figures).

Please see the revised Table 2., where we have added the variables.

Did authors find a dose-response relationship between travel time and survival? Please state whether the association was linear. Please also provide results from quantile (quartile?) or categorical analysis.

No dose-response relationship between travel time and survival was seen, please see K-M curves in Figure 3. We have now also included an additional categorical analysis comparing survival for patients with travel time \< 1 vs. patients traveling \> 1 h. Please see the revised statistical analysis section and the result of the new categorical analysis:

In the additional multivariable regression survival analysis where travel time was handled as a categorical variable (survival for patients with travel time \< 1 h was compared to patients traveling \> 1 h) we found no association between travel time and survival, either for patients with colon cancer

HR 0.92\[95% CI 0.71 - 1.19\] or rectal cancer HR 0.84 \[95% CI 0.52- 1.36\]

On page 23, If authors believe that other studies were affected by confounding factors such as age, SES, and co-morbidity, please describe the limitation of each study in detail. (e.g. those studies did not adjust for or measure these factors? If they had adjusted for SES, would they have observed the null?)

Please see the revised section of the discussion.

However, many of the previous studies in this research field from the U.S. adjusted for socioeconomy as a confounding factor, but still reported associations between longer travel time and worse colorectal cancer outcomes 2,4,8

On page 24, In the UK and France, positive or inverse associations were reported? Whenever authors reported the association in the previous studies, please state the direction of the association.

Please see the revised section of the discussion.

Associations between longer distance to care and worse survival have also been reported in European countries with national universal health care systems such as France or the U.K. 5,21

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

The requirements have been met in the resubmission.

2\. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them and whether the data in the Risk North Database is publicly available and b) the date range (month and year) during which patients\' medical records were accessed. If patients provided informed written consent to have data from their medical records used in research, please include this information.

Please see the revised version methods and ethics sections.

Ethics

The Regional Board of Ethics in Umeå approved the design of the Risk North database and the present research project. The patients did not provide informed written consent but all data were fully anonymised before access. All colorectal cancer patients in Sweden are informed about registration in the SCRCR (i.e. the primary source of data in the present study) and an opt-out procedure for registration is used in the SCRCR. The data in the Risk North Database is not publicly available according to the Swedish data protection law.

3\. To comply with PLOS ONE submission guidelines, in your Methods section, please provide additional information regarding your statistical analyses. For more information on PLOS ONE\'s expectations for statistical reporting, please see <https://journals.plos.org/plosone/s/submission-guidelines.#loc-statistical-reporting>.

Please see the revised statistical analysis section. We have added more information on proportion of distribution, p-values in the manuscript and the full regression analysis as a supplementary file

4\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Please see the revised cover letter.

Detailed data is not possible to share without a scientific collaboration. As the RISK North database includes many variables that makes a person potentially identifiable we cannot share data publically on a PLOS ONE home page according to the Swedish data protection law. If researchers would like to get access to repeat the analyses access request can be at <rccnorr@umu.se>

5\. We note that Figure 1 in your submission contains map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <http://journals.plos.org/plosone/s/licenses-and-copyright>.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1\. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (<http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf>) and the following text:

"I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<http://creativecommons.org/licenses/by/4.0/>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form."

Please upload the completed Content Permission Form or other proof of granted permissions as an \"Other\" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: "Reprinted from \[ref\] under a CC BY license, with permission from \[name of publisher\], original copyright \[original copyright year\]."

2\. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder's requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

Please see the new Figure 1, which created under CCO license. (Source: The Swedish Mapping Authority (Lantmäteriet), available according to open data license Creative Commons, CC0)

Reviewer \#1: This is an important contribution to the understanding of how access to services affects cancer outcomes. I have some queries and some concerns. The main concern is that the usual way of presenting data is that travel time is the independent variable and the outcome variable (survival, emergency surgery, stage etc) is the dependent variable. This is how the different curves in the Kaplan Meier plot are defined in Figure 3. However, in the tables the mean travel time is given as the dependent variable. I would expect to see, for example, what proportion of patients travelling \>50 minutes required emergency surgery. This would be consistent with the other studies of this topic that were cited.

Please see the revised Table 2. The table now presents travel time as the independent variable, defined in 10 minutes intervals.

I am not surprised that the K-M curves for rectal cancer are separated less then for colonic cancer. However the survival curve for 50-59 minutes appears to be an outlier. It would be good to see the 95% confidence interval of this curve in particular.

We believe that Figure 3 would be to cluttered if 95% CI curves were included. The main point from the K-M curves in Figure 3 is that there is no obvious association between travel time and survival.

There appear to be two different issues in the question of access. One is the distance decay effect seen in the studies cited by the authors, the other is the way in which distance is compensated in citizens\' approach to symptoms. This factor is likely to be relevant in Northern Sweden where the overall population density is very low but there is concentration around a few settlements. In this context, it is important to note that Kravdal (ref 25) found: \"most notably, those who lived in Oslo and Southern Norway had a relatively poor survival, given the size of the nearest hospital.\" If Southern Norway has the same characteristics as England & Scotland (and Denmark) and the rest of Norway resembles Northern Sweden, this would be an instructive finding in improving cancer services. Can the authors address this in heir discussion?

Regrettably, we have had some difficulties to understand this comment, since our study does not include hospital size as a variable. We have added information in the introduction and in the discussion in order to better describe the setting of this study.

Section in the introduction:

The Northern Healthcare Region has approximately 900 000 inhabitants living in an area of 224 000 km2, resulting in a population density of only 4 pop./km2. (U.K. 274 pop./km2, France 123 pop./km2) . The Region includes many rural areas where patients have to travel long distances to reach the nearest hospital (Figure 1).

Section in the discussion:

There are factors in the organisation of the health care system in the Northern Health Care Region in Sweden, which may mitigate health care disparities associated with longer distance to care:

The national health care system in Sweden is tax funded and provides care to all residents at low out-of-pocket cost.25 . In addition, all patients in Sweden are entitled to free or subsidized travel to care. All hospitals in the Northern Health Care Region are publicly owned and all have facilities to diagnose colorectal cancer. Surgical treatment, especially for rectal cancer, has however been centralised to fewer hospitals in the Region during the study period. Chemotherapy is given at most local hospitals under guidance from the only Oncology departments in the Region, located in Umeå and Sundsvall. In summary, all colorectal cancer patients in the Region can go to their local hospital, at a low cost, for diagnosis and in most cases also for treatment.

Reviewer \#2: This is an interesting manuscript about the travel time and outcomes for cancer patients in Northern Sweden. There are several aspects of this manuscript that dampen my enthusiasm for this manuscript, as described below.

1\. There needs to be a lot more detail on the setting of this study, as I suspect this is quite different than many other care delivery settings. Specifically, I would like to understand how the population density compares to other countries. I have a hard time knowing how 900,000 inhabitants in this area related to other areas. This seems very sparsely populated. Do many of these people live in small cities, is the distribution for across the area? It sounds as if the majority of the patients in the sample may be in what many other regions would consider rural or low volume settings. We also need information about availability of healthcare facilities and structure of these locations. I would want to know about both the cancer care delivery locations and access to ER/critical access centers. It would also be helpful to talk more about access in Sweden. Do most people go to a major surgery center and do they also get chemotherapy there? Without more information on context, this manuscript could be taken out of the appropriate context and difficult to relate to other care settings.

We have added information in the introduction and in the discussion in order to better describe the setting of this study. See above.

2\. I found the map to be somewhat confusing. Is the blue representing where the population of the study came from or just what would be that time to drive to the center. Are the crosses the health centers or cities? This could be a very useful map if there was a better sense of service locations of different types, population density and travel lines.

Please see the new Figure 1, the travel time isochrones are removed. Instead the figure just shows the location of the hospitals.

3\. I do not understand the comment that "Only patients who were treated with surgery were included in the multivariable analysis, as we wanted to study the impact of emergency compared to elective surgery." Most of these patients would likely have an elective colon operation? I was very confused by this selection criteria and how it was applied, and why. If you are only looking at people who are diagnosed due to an emergency (obstruction) this would be a very different population that the common colon and rectal cancer patient. In addition, you have many stages so I am not sure if I am just not understanding this.

Please see the revised data analysis section, for hopefully a better explanation.

Patients were excluded if data were missing for any of the co-variables in the multivariable analysis, and consequently we excluded all non-operated patients (missing data on the variable operation).

4\. It would be helpful to write in the manuscript the percent in each category, not only the category of less than 10 minutes. What you really want to understand are those who travel greater distances. This does not give the reader a sense of how you conceptualize the "longer travel" group. The authors should justify the use of these intervals and why this makes clinical sense. I am not sure that these categories reflect how patients and providers think about distance. What is a meaningful time difference?

Please see the revised Table 2 and the revised section in the discussion regarding travel time as a continuous or a categorical variable. In the revised Table 2 the patient´s characteristic - mean age, level of education, co-habiting status, tumour stage at diagnosis and type of surgery -- is stratified by travel time to the nearest hospital.

In our main survival analysis, we handled travel time as a continuous variable with 10-minute intervals rather than categorizing travel distance into, for example, quintiles or different cut-off values. This was done to avoid any presumptions on what is a meaningful travel time difference.

Now we added an additional analysis where travel time is handled as a categorical variable (\< 1 h vs. \> 1 h) But still, no association between travel time and survival was found,.

5\. In the results, please explain better the association. A p-value tells me little. I want to know for how much difference in travel time did you see what difference in age. Please add numbers to give context.

Please see the revised Table 2 -- row mean age by different travel time.

6\. This needs a sensitivity analysis or consideration of a categorical variable for travel time as the primary focus because the travel time is not linear. Conceptually, this also doesn't make sense. You want to understand the difference between those who travel far vs. not, rather than the difference between 10 minutes of travel. This difference means something entirely different if you are talking 10 vs. 20 minutes or 90 vs. 100 minutes.

Please see the results for the additional analysis for travel time as a categorical variable, and answer to comment 4.

7\. These units are challenging. I wonder if this is part of why the findings are as such because of the consideration of this variable as linear. When I look at figures, the authors do categorize better, but this is not coming through in the manuscript. I also would like to know how many people fall in these categories-the histogram is not labeled in a way that would correlate with the KM curves. I would also consider smaller number of categories as the numbers get very small in the survival analysis, which can lead to difficulty interpreting results.

Please see the revised Figure 2 with legend and Table 2.

8\. There have been other recent studies that look at time traveled to care and time to other hospitals, very similar to this study. Please soften this language or refer to the other studies that use time.

Please see the revised section of the discussion.

First, we measure travel time to care, whereas travel distance has been more commonly studied

9\. Please discuss why you think the universal health care system might tie into your results with some literature backing. This is a very interesting part of the discussion.

Please see the revised section of the discussion.

In a non-universal health care setting, socioeconomic differences between urban and rural populations could affect the access to care more than the distance to care itself. However, many of the previous studies in this research field from the U.S. adjusted for socioeconomy as a confounding factor, but still reported associations between longer travel time and worse colorectal cancer outcomes 2,4,8

Associations between longer distance to care and worse survival have also been reported in European countries with national universal health care systems such as France or the U.K. 5,21 Thus, true distance-related barriers, not confounded by differences in the patient´s socioeconomy, are probably also present and important in countries with universal health care.

Subsidized travel to care could be one way to mitigate distance related barriers to care. A study from Norway, with the same population pattern and health care system as Sweden, found no association between travel distance and cancer survival.26 In both Sweden and Norway, all patients are entitled to free or subsidized travel to care.27,28 In other universal (e.g., U.K.) or mixed health care systems (e.g., Australia), support with travel costs are based on income and/or distance to the caregiver. 29,30 The potential role of free or subsidized travel deserves more attention, especially with regard to patient adherence to repeated oncological treatment and outcome.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
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Travel time to care does not affect survival for patients with colorectal cancer in northern Sweden

A data linkage study from the Risk North database

PLOS ONE

Dear Dr. Sjöström,

Thank you for submitting your manuscript to PLOS ONE. One reviewer pointed out that additional reason for no association could be discussed apart from the subsidizing system. Maybe can authors get some clues from Kravdal et al.?  

Please submit a revised version of the manuscript that addresses the points raised.

One reviewer\'s comments;

They do not offer a clear suggestion as to why this might be apart from indicating the subsidised travel for patients\' attendance at hospital. My question is, do the Northern Swedish patients have good outcomes because they have a culture which enables them to compensate for their isolation? In this respect, is there anything to be learned from the study by Kradval (now ref 26) comparing the north-south geography of Norway with that of Sweden?

A few minor changes are required.

1\) please provide a citation for  \"The Northern Healthcare Region has approximately 900 000 inhabitants

living in an area of 224 000 km2 , resulting in a population density of only 4 pop./km2(U.K. 274 pop./km2 ,France 123 pop./km2)

2\) please specify whether authors used a two-sided test when presenting a significance level of .05. 

3\) In figure 2, please add tick marks on the X axis. For example, where is 110 min (n=110 (3%))? It is hard to figure it out exactly.  It is all the same color beyond 80-90 min.  Please also write \"(minutes)\" on the X axis label :Travel time (minutes)

4\) In table 2, what statistical method was used to obtain p values for either continuous or categorical variable? 

Please ensure that your decision is justified on PLOS ONE's [publication criteria](https://journals.plos.org/plosone/s/criteria-for-publication) and not, for example, on novelty or perceived impact.

==============================

Please submit your revised manuscript by July 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Jung Eun Lee

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

There are minor comments as follows.

Please specify statistical tests that authors used for new Table 2.

When authors discuss health care system in Sweden compared to other countries, please provide information on some statistics on health care delivery in Sweden to get clearer idea (e.g. population density, hospital facilities per population, fewer hospitals for surgical treatment for rectal cancer-\> did authors have some numbers?).

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This is a much clearer presentation of the data and the points have all been addressed with the exception of one, where the authors did not understand my point! To express it differently, the authors show the lack of distance decay in outcomes from colorectal cancer and also point out that these findings differ from the consensus in other literature. They do not offer a clear suggestion as to why this might be apart from indicating the subsidised travel for patients\' attendance at hospital. My question is, do the Northern Swedish patients have good outcomes because they have a culture which enables them to compensate for their isolation? In this respect, is there anything to be learned from the study by Kradval (now ref 26) comparing the north-south geography of Norway with that of Sweden?

Reviewer \#2: The authors have addressed the concerns of the reviewers well. I appreciated the additional context about the population evaluated in this paper.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Dr S. Michael Crawford

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236799.r004

Author response to Decision Letter 1

9 Jul 2020

Dear Editor!

Thank you for your further comments to the manuscript. We have adjusted the manuscript according to your suggestions. Hopefully the manuscript is now acceptable!

Our responds are given point-by-point below and highlighted in the manuscript.

Best Wishes, Olle Sjöström, Corresponding author.

One reviewer\'s comments;

They do not offer a clear suggestion as to why this might be apart from indicating the subsidised travel for patients\' attendance at hospital. My question is, do the Northern Swedish patients have good outcomes because they have a culture which enables them to compensate for their isolation? In this respect, is there anything to be learned from the study by Kradval (now ref 26) comparing the north-south geography of Norway with that of Sweden?

We agree with Dr S. Michael Crawford (Reviewer \#1) that the reasons to the good outcome in Northern Sweden might be found in protective factors not related the health care system. Differences on a health care system level with possible effects on the association between survival and distance to care are however easier to discuss since references describing different health care systems are more available and distinct. Psychosocial factor would be more speculative to discuss as we do not have any data to support it.

In the study by Kravdal et al the authors speculate that individuals living in Northern Norway - due to psychological or social factors are more used to travel far in their everyday life - thus reducing travel distance as a barrier to care. They also discuss the possibility of a healthier lifestyle among the population outside the city centres - resulting in a more favourable prognosis. Neither our study nor the study by Kravdal et al have however any results to support these by all means much plausible hypothesises.

But in order to broaden the discussion to factors outside the health care system we have added the following in the Discussion:

" Finally, there might be other factors - not related to the health care system - which explains the good outcome in Northern Sweden. As suggested in a Norwegian study, individuals living in rural areas might be more used to travel far in their everyday life - thus reducing travel distance as a barrier to care.28 "

A few minor changes are required.

1\) please provide a citation for \"The Northern Healthcare Region has approximately 900 000 inhabitants

living in an area of 224 000 km2 , resulting in a population density of only 4 pop./km2(U.K. 274 pop./km2 ,France 123 pop./km2)

Please see the revised part of the Introduction and new references 14 and 15.

2\) please specify whether authors used a two-sided test when presenting a significance level of .05.

We have changed the paragraph "To test for proposed associations, we used two-tailed between-subject Student's t-test for continuous parametric variables and Spearman's test for non-parametric ranked variables (α=0.05)" to "To test for proposed associations, we used two-sided between-subject Student's t-test for continuous parametric variables and Spearman's test for non-parametric ranked variables (α=0.05)"

3\) In figure 2, please add tick marks on the X axis. For example, where is 110 min (n=110 (3%))? It is hard to figure it out exactly. It is all the same color beyond 80-90 min. Please also write \"(minutes)\" on the X axis label :Travel time (minutes)

We have revised Figure 2 according to your suggestions, which made the histogram much easier to understand!

4\) In table 2, what statistical method was used to obtain p values for either continuous or categorical variable?

Please see the revised version of Table 2, footnotes indicating statistical method has been added.

Additional Editor Comments (if provided):

There are minor comments as follows.

Please specify statistical tests that authors used for new Table 2.

Please see 4) above!

When authors discuss health care system in Sweden compared to other countries, please provide information on some statistics on health care delivery in Sweden to get clearer idea (e.g. population density, hospital facilities per population, fewer hospitals for surgical treatment for rectal cancer-\> did authors have some numbers?).

Please see the revised section of the discussion:

"All 13 hospitals in the Northern Health Care Region are publicly owned and all have facilities to diagnose colorectal cancer. Each local hospital offers service to the population in its catchment area. The population, which is served per hospital, varies from approximately 25000 to 160000.14 Surgical treatment, especially for rectal cancer, has however been centralised to fewer hospitals in the Region during the study period. By the end of the study period, rectal cancer surgery was performed at only five hospitals. "

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This is a much clearer presentation of the data and the points have all been addressed with the exception of one, where the authors did not understand my point! To express it differently, the authors show the lack of distance decay in outcomes from colorectal cancer and also point out that these findings differ from the consensus in other literature. They do not offer a clear suggestion as to why this might be apart from indicating the subsidised travel for patients\' attendance at hospital. My question is, do the Northern Swedish patients have good outcomes because they have a culture which enables them to compensate for their isolation? In this respect, is there anything to be learned from the study by Kradval (now ref 26) comparing the north-south geography of Norway with that of Sweden?

Please see above!

Reviewer \#2: The authors have addressed the concerns of the reviewers well. I appreciated the additional context about the population evaluated in this paper.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

7\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer \#1: Yes: Dr S. Michael Crawford

Reviewer \#2: No
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Dear Dr. Sjöström,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Jung Eun Lee

Academic Editor

PLOS ONE

10.1371/journal.pone.0236799.r006
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PONE-D-19-34718R2

Travel time to care does not affect survival for patients with colorectal cancer in northern Sweden A data linkage study from the Risk North database

Dear Dr. Sjöström:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jung Eun Lee

Academic Editor

PLOS ONE
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